The Value of Further Research: The Added Value of Individual-Participant Level Data

Pedro Saramago (), Manuel A. Espinoza (), Alex J. Sutton (), Andrea Manca () and Karl Claxton
Additional contact information
Pedro Saramago: The University of York
Manuel A. Espinoza: Pontificia Universidad Católica de Chile
Alex J. Sutton: University of Leicester
Andrea Manca: The University of York

Applied Health Economics and Health Policy, 2019, vol. 17, issue 3, No 2, 273-284

Abstract: Abstract Judgements based on average cost-effectiveness estimates may disguise significant heterogeneity in net health outcomes. Decisions about coverage of new interventions are often more efficient when they consider between-patient heterogeneity, which is usually operationalized as different selections for different subgroups. While most model-based cost-effectiveness studies are populated with aggregated-level sub-group estimates, individual-level data are recognized as the best source of evidence to produce unbiased and efficient estimates to explore this heterogeneity. This paper extends a previously published framework to assesses the added value of having access to individual-level data, compared to using aggregate-level data only, in the absence/presence of mutually exclusive population subgroups. Supported by a case study on the cost-effectiveness of interventions to increase uptake of smoke-alarms, the extended framework provided a quantification of the benefits foregone of not using individual-level data, pointed to the optimal number of subgroups and where further research should be undertaken. Although not indicating changes in reimbursement decisions, results showed that irrespective of using aggregate or individual-level data, no substantial additional gains are obtained if more than two subgroups are taken into account. However, depending on the evidence type used, different subgroups are revealed as warranting larger research funds. The use of individual-level data, rather than aggregate, may however influence not only the extent to which an appropriate understanding of existing heterogeneity is attained, but, more importantly, it may shape approval decisions for particular population subgroups and judgements of future research.

Date: 2019
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40258-019-00462-x Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:aphecp:v:17:y:2019:i:3:d:10.1007_s40258-019-00462-x

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40258

DOI: 10.1007/s40258-019-00462-x

Access Statistics for this article

Applied Health Economics and Health Policy is currently edited by Timothy Wrightson

More articles in Applied Health Economics and Health Policy from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().